Innoviva Stock Discussion

Innoviva presents inefficiencies in capital allocation, given its low ROE and stunting earnings growth despite retaining all profits. Comparatively poorer performance to industry's 8.5% growth raises doubts about their reinvestment strategies. Caution advised due to its risk landscape.

Recent insider stock sale at Innoviva prompts concern given the timing and scale. The lack of insider ownership paired with their readiness to sell at current prices suggests no urgency to buy shares.